Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares
September 12 2018 - 8:15PM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage,
neurology-focused biopharmaceutical company, today announced the
pricing of its underwritten public offering of 4,500,000 common
shares pursuant to its existing shelf registration statement at a
public offering price of $14.00 per share. The gross proceeds to
Xenon from the offering, before deducting underwriting discounts
and commissions and other offering expenses payable by Xenon, are
expected to be $63.0 million. In addition, Xenon has granted to the
underwriters of the offering an option for a period of 30 days to
purchase up to an additional 675,000 common shares at the public
offering price, less the underwriting discounts and commissions.
The offering is expected to close on or about September 17, 2018,
subject to customary closing conditions.
Jefferies LLC and Stifel are acting as joint
book-running managers for the offering.
A shelf registration statement relating to the
common shares offered in the public offering described above was
filed with the Securities and Exchange Commission (SEC) on December
7, 2015 and declared effective by the SEC on January 5, 2016.
The offering is being made only by means of a written prospectus
and prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC’s website at www.sec.gov.
A final prospectus supplement and accompanying prospectus will be
filed with the SEC. When available, copies of the final prospectus
supplement and the accompanying prospectus may also be obtained by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by email at Prospectus_Department@Jefferies.com, or by phone at
(877) 821-7388; or from Stifel, Nicolaus & Company,
Incorporated, One Montgomery Street, Suite 3700, San Francisco,
California 94104, Attn: Syndicate, by telephone at (415) 364-2720
or by email at syndprospectus@stifel.com.
No securities are being offered or sold,
directly or indirectly, in Canada or to any resident of Canada.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy the securities being
offered, nor shall there be any sale of the securities being
offered in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
the Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. These forward-looking statements are not based on
historical fact, and include statements regarding the anticipated
closing of the public offering. These forward-looking statements
are based on current assumptions that involve risks, uncertainties
and other factors that may cause the actual results, events or
developments to be materially different from those expressed or
implied by such forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include, but
are not limited to, uncertainties related to market conditions and
the completion of the public offering on the anticipated terms or
at all, as well as the other risks identified in our filings with
the SEC and the securities commissions in British Columbia, Alberta
and Ontario. These forward-looking statements speak only as of the
date hereof and we assume no obligation to update these
forward-looking statements, and readers are cautioned not to place
undue reliance on such forward-looking statements.
Xenon Investor/Media Contact:Jodi Regts Phone:
778.999.5634 Email: investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Apr 2023 to Apr 2024